Prostate Cancer Testing Kits Market - Forecast(2024 - 2030)
Prostate Cancer Testing Kits Market Overview
Prostate Cancer Testing Kits Market size is estimated to
reach $1.9 billion by 2027, growing at a CAGR of 11.4% during the forecast
period 2022-2027. The earliest step in testing for prostate cancer is a
prostate-specific antigen (PSA) test. PSA is a protein prepared by the
prostate, the tiny gland below the bladder. In certain cases, an elevated PSA
level can be a sign of prostate cancer. However, not all elevated PSA levels are
an indication of prostate cancer. PSA is also discovered in enlargement of the
prostate (benign prostatic hyperplasia), infections and inflammation of the
prostate (prostatitis). Since PSA is detected in the blood, a PSA test is normally
taken with a finger prick. A PSA test will not offer sufficient information for
a diagnosis; however, it may assist the physician in making a determination if
cancer is probable and what to do next. While PSA tests once needed the patient
to be present in a laboratory or at the office of the physician, a test can
presently be administered from the home of the patient. PSA tests can also be utilized
to evaluate the efficiency of treatments and supervise progress. The tests
could be performed to supervise for recurrence of cancer or other conditions.
As per Health line, the picks for the best at-home PSA tests include
Lets Get Checked priced at $99, Allergy Test priced at &45, Pinnacle BioLabs
priced at $49.99, imaware priced at $89 and Quest Direct priced at $69. Trans rectal
ultrasound is a vital instrument in the detection and management of prostate
cancer. Its role is to recognize
and characterize focal lesions prior to capsular invasion and metastases and to
lead biopsy of the prostate. Prostate Health Index is a test that foresees the hazard of having
prostate cancer. Prostate Health Index is utilized instead of the PSA test for prostate cancer
detection and prostate cancer screening. A digital rectal examination (or exam) is utilized to detect
if one may have a prostate issue or prostate cancer. It includes the physician
or nurse feeling the prostate by way of the wall of the back passage (rectum). One
Prostate Cancer Testing Kits industry application is in prostate cancer
diagnostics.
The heightening application of At Home PSA Prostate Cancer
Test Kits for screening of prostate cancer and increasing utilization of trans rectal
ultrasound for detection and management of prostate cancer is set to drive the Prostate
Cancer Testing Kits Market. The soaring advantages of screening for prostate
cancer like detecting prostate cancers that can be at great hazard of
spreading, so that they can be treated prior to their spread thereby decreasing
the possibility of a loss of life from prostate cancer in certain men and the
inclination of certain men to be informed if they have prostate cancer are set
to propel the growth of the Prostate Cancer Testing Kits Market during the
forecast period 2022-2027. This represents the Prostate Cancer Testing Kits
Industry Outlook.
Report Coverage
The report: “Prostate Cancer Testing Kits
Market Report - Forecast (2022-2027)” by Industry ARC, covers an
in-depth analysis of the following segments in the Prostate Cancer Testing Kits Market.
Key Takeaways
- Geographically, North America (Prostate Cancer Testing Kits Market) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the great predominance of prostate cancer requiring the utilization of trans rectal ultrasound for detection and management of prostate cancer and the increasing government initiatives to expedite early diagnosis in the North American region.
- Prostate Cancer Testing Kits Market growth is being driven by the development of technologically progressive products including portable and fast prostate cancer screening kits, the increasing count of digital rectal examinations and the introduction of numerous investigations for superior prostate cancer diagnostics. However, owing to the predominantly inactive course of this ailment and the not particular character of the Prostate-Specific Antigen (PSA) test, the increased occurrence has broadly been connected with cancers that would not go on to bring about loss of life (clinically insignificant), resulting in an overdiagnosis challenge and a resultant overtreatment ramification. This is one of the major factors hampering the growth of Prostate Cancer Testing Kits Market.
- Prostate Cancer Testing Kits Market Detailed Analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Prostate Cancer Testing Kits Market report.
Prostate Cancer Testing Kits Market: Market Share (%) By Region, 2021
For more details on this report - Request for Sample
Prostate Cancer Testing Kits Market Segment Analysis – By Product Type:
The Prostate Cancer Testing Kits Market based on product type can be further segmented into Prostate-Specific Antigen Test Kit (AccuQuik Test Kits), PSA SPOT Test Kit, Galleri® Multi-Cancer Early Detection Test, Prostate Testing Kit PSA Professional Cancer Screening Tests 5 Tests, PSA Rapid Test Kits, At-Home PSA Test Kits and Others. The Prostate-Specific Antigen Test Kit (AccuQuik Test Kits) Segment held the largest prostate cancer testing kits market share in 2021. This growth is owing to the surging application of prostate-specific antigen test kit diagnostic test for detecting the level of prostate specific antigen which is utilized to diagnose prostate issues from specimens of serum/plasma. Prostate Cancer Testing Kits industry application may involve testing for prostate cancer or prostate cancer screening. The heightening application of AccuQuik Test Kits for the diagnosis of early prostate cancer is further propelling the growth of the Prostate-Specific Antigen Test Kit (AccuQuik Test Kits) segment.
Furthermore, the PSA Rapid Test Kits segment
is estimated to grow with the fastest CAGR of 12.1% during the forecast period 2022-2027
owing to the heightening application of PSA rapid test kits, also termed
one-step PSA tests, as an accelerated direct binding PSA immunoassay for the
qualitative detection of Prostate Specific Antigen (PSA) in human serum
specimen.
Prostate Cancer Testing Kits Market Segment Analysis – By End User:
The Prostate Cancer Testing
Kits Market based on end user can be further segmented into Hospitals And
Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research
Centers and Others. The Diagnostic
Centers Segment held the
largest prostate cancer testing kits market share in 2021. This growth is owing to the surging
application of different prostate cancer diagnostic techniques including the application of prostate cancer testing kits on patients as required. The diagnostic
centers expedite strong, on-time, cost-effective and high-quality diagnostic
care and services in the secure healthcare environment and are useful for outsourcing bulk diagnostics tests from consulting physicians/healthcare institutions for superior
customer services which are further propelling the growth of this segment.
Furthermore, the Hospital
And Clinics segment is estimated to grow with the
fastest CAGR of 12.7% during the forecast
period 2022-2027 owing to the extensive application of free and total
Prostate-Specific Antigen (PSA) tests in hospitals and clinics and the
increasing application of PCA3 test in a few private hospitals and clinics
owing to the requirement of greater research regarding how capably it performs.
Prostate Cancer Testing Kits Market Segment Analysis – By Geography:
The Prostate Cancer Testing
Kits Market based on geography can be further segmented into North America,
Europe, Asia-Pacific, South America and Rest of the World. North America (Prostate
Cancer Testing Kits Market) held the largest prostate
cancer testing kits market share with 30% of the overall market in 2021. The growth of this region is
owing to the agreeable government backing for prostate specific antigen
(PSA) test in the U.S. in the North American region. The soaring existence of key players like
AccuQuik Test KitTM in the U.S. and the increasing predominance of
prostate cancer is further propelling the growth of the Prostate Cancer
Testing Kits Market in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the rising pervasiveness of chronic ailments attributed to the altered lifestyle based on intake of western diets and inactive lifestyle in the Asia-Pacific region. The increasing predominance of prostate cancer is further fuelling the progress of the Prostate Cancer Testing Kits Market in the Asia-Pacific region.
Prostate Cancer Testing Kits Market Drivers
Surging Accessibility of Prostate Cancer Testing Kits are Projected to Drive the Growth of Prostate Cancer Testing Kits Market:
Digital
rectal examination and prostate-specific antigen tests are the typically
utilized prostate cancer screening tests. Trans rectal ultrasound (TRUS) is a
5- to 15-minute outpatient procedure that utilizes sound waves to develop a
video image of the prostate gland. The home prostate test kit is an effortless
and reliable way to assess the PSA (Prostate Specific Antigen) level in the
blood - which is useful to assist in diagnosing issues with the prostate. This
home prostate test is a rapid test intended as an initial semi-quantitative
test to discover PSA blood levels greater than 4ng/ml in whole blood. The test needs
to be utilized as a screening test and as a support for diagnosing elevated
levels of PSA. Any positive outcomes need to be followed up by a visit to the
physician who may request further tests. The surging accessibility of Prostate
Cancer Testing Kits is therefore fuelling the growth of the Prostate Cancer
Testing Kits Market during the forecast period 2022-2027.
Soaring Innovations in Prostate Cancer Testing Kits are Expected to Boost the Growth of the Prostate Cancer Testing Kits Market:
Apart from the
digital rectal examination were in, the health care provider inserts a gloved
finger into the rectum and feels the prostate for hard, lumpy, or abnormal
areas with the test consuming only a few minutes to finish, towering
innovations in prostate cancer testing kits have been noted. A trans rectal
ultrasound (TRUS) is an ultrasound technique that is utilized to view a man’s
prostate and surrounding tissues. In January 2022, a novel medical development
was constructed to offer fast and useful testing for men who may be potential
prostate cancer patients. The screening kit involves a specially designed
system that could relay any early warning signs of the condition. The principal
purpose of the investigation was to advance the accessibility of this typically
overlooked medical technology to communities with a high incidence of prostate
cancer and individuals with restricted to no access to proper health care. The novel
medical testing equipment for discovering hints of prostate cancer was
presented in the form of minimal and economical architecture. The constituents
of the screening kit include a small cube-shaped calibrating device that scales
to 1.6 inches and a simple test strip. The device was produced to offer the essential
details of prostate cancer by way of a rare marker termed as the prostate-specific
antigen of PSA. The testing is not too complicated and is similar to other
tests, needing just a single drop of blood from the subject. The prostate
screening device does not consume too much time, permitting patients and
experts to get a hold of the outcomes in just a few minutes. The samples will
then be tested and the outcomes will be available in 10 to 15 minutes. Rapid
testing offers a much quicker detection and can be used instantly for further
insights and additional tests when required. The soaring innovations in Prostate
Cancer Testing Kits are therefore driving the growth of the Prostate Cancer
Testing Kits Industry during the forecast period 2022-2027.
Prostate Cancer Testing Kits Market Challenges
Challenges of Prostate Cancer and Limitations of Prostate-Specific Antigen (PSA) are Hampering the Growth of the Prostate Cancer Testing Kits Market:
Prostate
cancer is the most typical non-skin cancer in men with nearly $12 billion spent
annually on the treatment of prostate cancer. Nearly 500,000 biopsies are carried
out every year on men, many of which are possibly inessential. It has been widely recognized, that the clinical
challenges in prostate cancer are numerous and rely on the disease category at
patient presentation. It is helpful to view prostate cancer in a range of
distinct clinical categories as these categories will define not only the suitable
treatments but also the present clinical challenges. Though prostate specific
antigen (PSA) screening for prostate cancer has been a standard of care (SOC)
for numerous years, its advantages have caused debate currently. The United
States Preventive Services Task Force (USPSTF) altered its guidelines in 2018
advising men 55-69 years to make an informed selection and discuss with their physician
whether PSA screening is right for them while suggesting against screening for
men over 70 years of age. This alteration in guidance came about subsequent to
a review of published data of 1.9 million men on the application of PSA testing
to screen for cancer-based on the potential harms and advantages of PSA
screening. The limitations of PSA include reduced sensitivity and specificity
for prostate cancer and PSA levels being raised by benign prostatic hyperplasia
(BPH) and prostatic inflammation or lower urinary tract infection. When PSA outcomes
are in the “gray zone”, additional factors like age, family history, ethnicity
and digital rectal examination (DRE) factor into the shared decision-making
discussion about the prostate biopsy. PSA cannot differentiate high-grade from low-grade cancer and is not prostate cancer-specific These issues are thus hampering
the growth of the Prostate Cancer Testing Kits Market.
Prostate Cancer Testing Kits Industry Outlook
Novel product
launches, mergers and acquisitions, development of technologically progressive
devices, partnerships and collaborations are key strategies adopted by players
in the Prostate Cancer Testing Kits Market. The top 10 companies in the
Prostate Cancer Testing Kits Market are:
- AccuQuik Test KitTM
- LetsGetChecked
- Allergy Test
- Pinnacle BioLabs
- imaware
- QuestDirect
- SELFCheck Prostate (PSA) Health Home Test Kit
- Galleri Test
- Prostate Testing Kit PSA Professional Cancer
Screening Tests 5 Tests
- Rapidfor™ PSA Rapid Test Kit
Recent Developments
- In March 2022, LetsGetChecked, a leading healthcare solutions
firm, declared that it will acquire Veritas Genetics Inc. and Veritas
Intercontinental, pioneers in genomics that share a scalable platform allowing
the rapid interpretation of genetic information from a single gene to the whole
genome. These acquisitions indicate a critical advancement in LetsGetChecked’s
mission to empower individuals to take control of their health and allow both
consumers and healthcare partners to be more keyed up in healthcare management.
- In September 2020, Houston-based testing and screening provider imaware™ teamed with HALO Diagnostics (www.halodx.com) to advance early detection and link patients to the most recent advances in prostate cancer diagnostics and treatment solutions. imaware™ provides a self-collected testing solution for men to learn their PSA (Prostate Specific Antigen) level and evaluate their prostate cancer risk while also reducing doctor-patient interaction during the COVID-19 pandemic.
- In April 2020, Bio-Techne Corporation declared that Exosome Diagnostics, a Bio-Techne brand, is introducing an ExoDx™ Prostate Test At-Home Collection Kit for patients who are concerned regarding their prostate health index. Millions of men currently had appointments cancelled for significant procedures, like biopsy, to detect the presence of prostate cancer owing to Shelter in Place orders issued to decrease the spread of COVID-19. The at-home collection kit offers an instant and cost-efficient solution that allows a telemedicine/telehealth opportunity for physicians and their patients who share frustration, anxiety and fear over whether the patient harbors high-grade prostate cancer. This concludes the Prostate Cancer Testing Kits industry Outlook.